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Abstract
Anion exchange (AE) proteins are present in hum an neurons 
in the brain. Immunohistochemical data indicate that their 
apparent expression level increases with age, and especially 
with degeneration in Alzheimer’s disease-affected brain areas. 
The increase in immunoreactivity is probably caused by 
changes in AE structure that lead to an increased accessibility 
o f hitherto hidden epitopes. These epitopes correspond to 
regions in the membrane domain that are involved in genera­
tion of senescent cell-specific antigen from AE I in aging eryth­
rocytes. Elucidation of the molecular nature of these changes 
and the underlying mechanisms, will lead to insight in the pro­
cesses that govern aging- and degeneration-associated pertur­
bation of membrane integrity. AE-mediated chloride/bicar­
bonate exchange is a major component in  the regulation of 
intracellular pH. The functional consequences o f changes in 
AE structure may range from acidosis, disturbance of cytoskel- 
eton integrity, and untimely or impaired recognition o f cells 
by components of the immune system, such as microglia. A 
molecular and physiological description of these changes will 
establish AE proteins as valuable tools in elucidating the pro­
cesses of normal aging, and the disturbances in aging-related 
diseases such as Alzheimer’s disease.
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Introduction
Proteins of the anion exchanger (AE) gene 
family have been found in all cells examined 
so far [ 1-3]. The AE proteins share a C-termi- 
nal, highly homologous membrane domain 
(~ 50 kD) that is mainly responsible for anion 
exchange, and a more variable N-terminal, 
cytoplasmic domain (50-80 kD) that binds 
cytoskeletal and other peripheral proteins. 
The functions of erythrocyte AE1 (or band 3), 
the most extensively studied member of this 
family, are the exchange of chloride and bicar­
bonate across the plasma membrane, thereby 
facilitating transport of carbon dioxide 
through the body, and anchoring the spectrin/ 
actin cytoskeleton to the plasma membrane, 
by providing a binding site for ankyrin [2], In 
addition, the cytoplasmic domain may play a 
role in regulation of anion transport activity 
[4], as well as in the regulation of cell metabo­
lism by the binding of glycolytic enzymes such 
as glyceraldehyde-3-phosphate dehydroge­
nase [5, 6]. In other cells, the anion transport 
activity of AE1 and other AE proteins is 
involved in regulation of intracellular pH, 
chloride concentration, and cellular volume 
[7-9]. AE1 and AE3, but not AE2 or the trun­
cated variants of AE1, have a high affinity for 
ankyrin [10]. The more extensive variation in 
the cytoplasmic domain may reflect the varia­
tion in cell type-specific cytoskeleton architec­
ture.
AE1 has also been identified as the precur­
sor of the senescent cell-specific antigen 
(SCA), responsible for recognition and subse­
quent removal of old and damaged erythro­
cytes by the immune system [11], Changes in 
AE1 conformation, presumably triggered by 
oxidation and/or proteolytic degradation, oc­
cur during normal erythrocyte aging. These 
changes do not only affect anion transport 
and the interaction of AE1 with the cytoskele­
ton, but also result in the appearance of the
neoantigen SCA. Binding of SCA by autolo­
gous IgG, possibly in a complex with C3b 
[12], leads to recognition and removal of old 
cells from the circulation by macrophages. 
The process that generates SCA from AE1, 
which may be accelerated during organismal 
aging [ 13], is active in other cell types as well 
[111-
Aging is the most important risk factor for 
Alzheimer’s disease (AD): the neuropsycho­
logical and the neuropathological characteris­
tics of AD show a broad overlap with the 
characteristics of normal, physiological aging 
[14-18]. Normal brain aging is accompanied 
by a number of changes, such as apparent 
neuron loss in hippocampus and cortex areas, 
accumulation of lipofuscin, an increase in the 
num ber of corpora amylacea, a gradual accu­
mulation of amyloid plaques and neurofibril­
lary tangles, and an increase in number and/ 
or reactivity of astrocytes [14-16, 18], The 
neuronal membrane is probably the site at 
which aging-related changes most directly af­
fect cellular homeostasis [19]. Aberrant pro­
cessing and cleavage of amyloid precursor 
protein ((3APP), as well as abnormal phos­
phorylation of tau, are likely to be involved 
in the etiology of the AD-specific lesions 
amyloid plaques and neurofibrillary tangles 
[20, 21]. We propose that these events are 
secondary to and signposts of perturbation of 
neuronal membranes. This hypothesis is 
based on observations as: (1) the cleavage 
sites of the A|3 peptide, as well as the identi­
fied mutations in (3APP, are all located with­
in or close to the putative membrane domain 
of (3APP [20]; (2) minute lesions in the neu­
ronal membrane probably precede deposition 
of A(3 in diffuse plaques [22]; (3) structural 
and functional analyses have revealed AD- 
related alterations in neuronal membranes 
[19, 23-25]; (4) recently, mutations in two 
related genes that encode integral membrane 
proteins were identified as responsible for
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over 80% of the cases of familial Alzheimer’s 
disease [26, 27]. These mutations are located 
close to predicted membrane-spanning re­
gions of these proteins. Together, these data 
suggest that aging-related phenomena are 
more pronounced in the AD-affected brain, 
and are concentrated at the neuronal mem­
brane, but they provide no clues to the un­
derlying mechanisms. It has been put for­
ward that AD-related changes in cellular 
membranes could result in changes in signal 
transduction, similar to those observed dur­
ing normal aging in neural and nonneural 
cells [28].
Considering the central position of changes 
in structure and function of AE1 in erythro­
cyte aging, the emerging central role of AE 
proteins in cellular homeostasis, and especial­
ly the apparent changes in AE protein struc­
ture that occur during aging and degeneration 
in the human neuron, we see the AE proteins 
as the common denominators of physiological 
and pathological neuronal aging in the human 
brain. Here we will review the data that have 
led to this view, and present and discuss new 
data that support and extend it.
Materials and Methods
Neuropathology and Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue from 
control and AD patients (up to 10 h  postmortem) was 
used for neuropathological examination and diagnosis 
as described before [29-34]. Plaques and tangles were 
encountered only sporadically in the brains of control 
patients. Immunohistochemistry was performed on 
formaldehyde or paraformaldehyde/sublimat-fixed tis­
sue. Sections were counterstained with hematoxylin. 
Control incubations contained preimmune sera. Im- 
munostaining was performed with the avid in-biotin- 
peroxidase technique [29-34].
Immunoblotting
Immunoblot analysis was performed on frozen tis­
sue fractions from the same brains used for neuropa­
thological and immunohistochemical analysis, using
antiserum dilutions o f  1:200-1:500, as described be­
fore [29-34].
Antibodies
The polyclonal antibody W P944 was raised against 
a soluble part o f  the cytoplasmic domain of erythrocyte 
AE1 [Bosman et a l ,  unpubl. results]. The monoclonal 
antibody Bill. 136 recognizes the amino acid residues 
22-27 of hum an AE1 [35]. The antiserum against 
hum an erythrocyte ankyrin was a gift from Dr. J.C. 
P inder (University o f  London» London, UK). The 
monoclonal antibodies 4.15 against amino acids 628- 
642 and 4A3 against amino acids 650-658 o f hum an 
AE1 were gifts from Dr. I.W. Sherman (University o f 
California, Riverside, Calif., USA).
pH Measurements
The contribution o f  the various ion transporters to 
the regulation of intracellular p H  was determined with 
the fluorescent probe 2',7'-bis-(2-carboxyethyl)-5-(and- 
6)-carboxyfluorescein (Molecular Probes, Eugene, 
Oreg., USA), following the procedures described be­
fore [36,37].
Cell Lines
The neuroblastoma cell line IMR-32 (American 
Type Culture Collection, Rockville, Md., USA) was 
cultured in RPM I m edium  (Dutch modification) con­
taining 10% fetal calf serum (Life Technologies, Breda, 
The Netherlands).
Results and Discussion
Early in the recent explosion of research on 
Alzheimer’s disease, it was postulated that 
accelerated cellular aging in general, and neu­
ronal aging in particular, might lie at the ori­
gin of AD [14]. This hypothesis was difficult 
to falsify, as little was known about the nor­
mal neuronal aging process. In contrast, the 
aging-related changes in structure and func­
tion of erythrocyte AE1 constitute a useful 
paradigm for the final stages in the cellular 
aging process [11]. M easurement of aging- 
related parameters of erythrocyte AE1 sug­
gested that the cellular aging process is dis­
turbed in patients with Alzheimer’s disease 
[38]. Comparison with other types of demen­
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tia, including the dementia syndrome ob­
served in elderly individuals with trisomy 21, 
indicated that perturbation of AE1 structure 
and function might occur early in life [39]. 
Recently obtained results, however, indicate a 
considerable variation in AE1 aging parame­
ters between individuals, as well as variation 
in time within one individual. These varia­
tions largely obscure any AD-specific phe­
nomena, especially as these variations may 
also occur in healthy, very old individuals 
[Bosman et al.5 in preparation]. This conclu­
sion seems to apply to all findings in nonneu­
ronal, peripheral cells [40],
Since the first description of the presence 
of band 3-related proteins in nucleated cells 
[41], proteins of the AE family have been 
found in all cells examined so far [3]. In neu­
ronal cells, AE proteins seem to have the same 
functions as AE1 in erythrocytes, such as an­
ion transport, ankyrin binding, and SCA gen­
eration [42]. Differentiation in vitro results in 
increased AE1 and SCA expression at the cell 
surface [43]. Various AE proteins (AE1, AE2 
and AEO, an AE protein with structural ele­
ments of AE1 and AE2 [33]) are expressed in 
human neurons, and the neuronal expression 
of at least one of these proteins increases with 
age [33, 44]. Immunoabsorption studies indi­
cate that SCA is generated on brain AE1, and 
SCA-antibodies label fibrillary structures in 
sections from old, but not from young brains 
[11].
In Alzheimer’s disease-affected brain ar­
eas, some anti-AEl antisera show an in­
creased immunoreactivity especially in large 
pyramidal cells with a degenerative morphol­
ogy that do not (yet) contain mature neurofi­
brillary tangles [30, 45]. An increased immu- 
noreactivity, both in the number of reactive 
cells and in the reactivity per cell, is observed 
especially with antibodies against epitopes of 
the membrane domain of AE1 (fig. ID, E). 
Antibodies against the cytoplasmic domain of
AE1 or AE2 do not show this increase 
(fig. 1A-C). These findings confirm and ex­
tend previous data [33, 45, 46]. Especially 
antisera against putative components of SCA 
in the AE1 membrane domain react with 
corpora amylacea in Alzheimer’s disease-af­
fected brain [34]. Corpora amylacea are lami­
nated hyaline bodies, with a protein part that 
contains proteins associated with the neuron­
al and glial cytoskeleton and membrane. 
Their num ber increases with age and AD [34]. 
We have not found significant quantitative or 
qualitative differences in AE expression at the 
protein level when comparing immunoblots 
of Alzheimer and control brain tissues (fig. 2, 
see also [30]). Preliminary results of semi- 
quantitative measurement of AE1 expression 
at the RNA level do not indicate increased 
expression of AE1 (or AEO and AE2) in AD- 
affected temporal cortex tissue [Bosnian et al., 
unpubl. observations]. However, qualitative 
differences in immunoblot protein patterns
Fig. 1. ïmmunohistochemical analysis of Alzhei­
mer and control hippocampus tissue with antibodies 
specific for various domains of anion exchange pro­
teins and ankyrin. A Control hippocampus, monoclon­
al antibody Bill, 136 against amino acids 22-27 of AE1. 
x 400. B Alzheimer hippocampus, Bill. 136. x400. 
C Alzheimer hippocampus, polyclonal antiserum 
WP944 against a soluble, cytoplasmic fragment of 
erythrocyte AE1. x400. D Alzheimer hippocampus, 
monoclonal antibody 4.15 against amino acids 628- 
642 in the fourth extracellular loop of the membrane 
domain of A EL x400. E Alzheimer hippocampus, 
monoclonal antibody 4A3 against amino acids 650- 
658 in the fourth extracellular loop of AE1. x400. 
F Alzheimer hippocampus, a polyclonal antiserum 
against erythrocyte ankyrin. x 400. Semiquantitative 
analysis shows no differences between Alzheimer and 
control tissues for antibodies BUI, 136 (A, B) and 
WP944 (C), bu t a significantly increased immunoreac- 
tion in Alzheimer tissue for antibodies 4.14 (D) and 
4A3 (E). The highly variable immunoreaction of the 
anti-ankyrin antiserum obscures any possible differ­
ences between Alzheimer and control tissue.
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Fig. 2. Immunoblot analysis of 
control (C) and Alzheimer (A) hip­
pocampus fractions with Bill. 136 
against the cytoplasmic domain of 
AE1. P = 40,000 g particulate frac­
tion containing intracellular and 
plasma membranes; S = superna­
tant fraction containing cytosolic 
proteins and smaller vesicles. A 
main immunoreactive protein of 
the expected molecular weight of 
AE1 (95 kD) is found especially in 
the membrane fractions (P), with­
out any significant differences be­
tween control (Ci and C2) and Alz­
heimer (AI and A2) fractions.
have been reported with an antiserum against 
a peptide consisting of amino acids 812-827 
of AE1 [45]. This antiserum also stained amy­
loid plaques, as did the antibody against a 
peptide in the fourth extracellular loop of AE1 
(fig. ID). In general, those antibodies against 
membrane-bound epitopes that react espe­
cially with polypeptides smaller than intact 
AE proteins on brain immunoblots, or with 
erythrocyte AE1 fragments generated in vitro, 
show increased immunoreactivity in sections 
of AD-affected brain areas when compared 
with control sections [34, 47]. The changes 
in immunoreactivity are accompanied by 
changes in anion transport [48].
From such data we conclude that neuronal 
AE proteins undergo specific structural 
changes in the membrane of aging and espe­
cially degenerating neurons. Such changes re­
sult in a conformation that is recognized by 
antisera directed against epitopes of the mem­
brane domain, which are not accessible in the 
healthy neuron. The strongest reactions are 
observed with antisera against components of 
the senescent cell antigen SCA that originates 
from AE1 in aging erythrocytes [11]. This 
conclusion indicates that the processes that 
lead to SCA generation from AE1 in aging
erythrocytes may also occur in aging and de­
generating neurons in the human brain. At 
present, there is only circumstantial evidence 
for the molecular nature of these processes, 
such as aging-associated oxidation, either in 
AE1 itself or in other membrane components, 
and/or activation of specific proteases [11].
A number of considerations, however, 
cloud the view sketched above. First, the 
known members of the AE family share a high 
degree of homology in their membrane do­
main [3], including the epitopes that display 
increased expression in aging and AD-af­
fected neurons. As at least three AE proteins 
are present in human neurons [33], it is not 
clear which AE proteins in which type of neu­
rons are responsible for the phenomena ob­
served so far. Second, not all AE isoforms and 
variants may be equally detectable. We have 
observed in AD brains an immunoreaction in 
neurons, e.g. granule cells in the dentate gyrus, 
that were negative in nondemented brains 
[47]. In addition, we have seen AE immuno­
reaction only in neuronal cells, whereas others 
have found indications for the presence of AE 
proteins in astroglia as well [11, 49]. These 
results may be caused by the ability of antisera 
against membrane epitopes to reach these epi-
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topes only in degraded and/or incomplete 
AE1 molecules [34]. Third, the increasing 
number of splice variants within the AE fami­
ly constitutes another complicating factor. 
For example, not only are there a number of 
AE1 variants with different cytoplasmic do-
> +
mains [3, 50], some AE proteins may have a 
complete cytoplasmic domain, but a consider­
ably shortened membrane domain [51]. The, 
mostly undocumented, reports of unexpected 
mRNAs that may lack variable parts of the 
membrane domain [1, 13] add to the suspi­
cion that there may be a plethora or AE iso­
forms ‘out there’. A careful combination of 
immunocytochemical and in situ hybridiza­
tion methods will be necessary to distinguish 
between the numerous possibilities. Finally, 
various isoforms may end up in various cell 
compartments, depending on interaction of 
the cytoplasmic domain with cytoskeletal pro­
teins such as ankyrin early in the synthesis 
pathway [50, 52], and/or the presence of spe­
cific sorting signals. It is noteworthy that an 
antiserum raised against a cytoplasmic frag­
ment of AE1 is the only antiserum so far, that 
shows a reactivity concentrated at the plasma 
membrane (fig. 1C). Most other antisera dis­
play a mostly intracellular, dotted pattern [30, 
53].
The anti-ankyrin antiserum stains both 
neurons and astrocytes (fig. IF). This is, to 
our knowledge, the first immunohistochemi- 
cal evidence for the presence of ankyrin-like 
proteins in the human brain. We could not 
demonstrate an Alzheimer-related degrada­
tion of ankyrin, as shown for fodrin, another 
neuronal cytoskeleton protein [45]. This is 
probably due to the sensitivity of ankyrin to 
degradation [Pinder, pers. commun.] that 
may occur even during very short (3 h) post­
mortem delay and subsequent tissue fragmen­
tation [Bosnian et a l, unpubl. results]. This 
conclusion is supported by the considerable 
interindividual variation that is shown by
immunohistochemical analysis, as observed 
with various antisera against hum an erythro­
cyte ankyrin [Van W orkum et al., unpubl. 
observations]. The ankyrin that is present in 
astrocytes (fig. IF) may interact with AE pro­
teins that are different from the neuronal iso­
forms. Aging and Alzheimer-related perturba­
tion of AE structure may affect the interaction 
between AE proteins and cytoskeletal ele­
ments in brain cells, as in aging erythrocytes 
[11]. Proteins related to erythrocyte protein 
4.1, one of the ligands of AE1, are present in 
neurofibrillary tangles [54], and preliminary 
data indicate that AE1 interacts with proteins 
of the neuronal cytoskeleton, that have been 
implied in the etiology of AD [Bosman et al.3 
unpubl. results].
As discussed above, structural changes in 
the AE membrane domain are the most con­
spicuous phenomena in AE proteins in the 
degenerating hum an neuron. The membrane 
domains of the known AE proteins are all 
involved in chloride/bicarbonate exchange- 
related regulation of intracellular pH [1,2], In 
order to assess the relative importance of 
intact AE activity in maintenance of pHi, we 
measured the capacity of IMR-32 neuroblas­
tom a cells -  a cell line that is also used as a 
model system to investigate AD-related pro­
cesses [55] -  to regulate pH i in various cir­
cumstances. In these cells, pH i recovery after 
acidosis is incomplete in the absence of bicar­
bonate (fig. 3A), but cells do recover in the 
presence of bicarbonate (fig. 3B). This recov­
ery is completely inhibited by DIDS, a high- 
affinity ligand of AE proteins (fig. 3C), and 
only partially dependent on extracellular sodi­
um (fig. 3C). These data indicate that bicar­
bonate transport across the neuronal mem­
brane is the major pHi-regulatory system in 
neuronal cells, and that at least part o f the 
bicarbonate transport can be contributed to 
AE-catalyzed chloride/bicarbonate exchange. 
Intracellular pH  plays an im portant role in
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7 .6 5 - 1  A
Fig. 3. Contribution of AE-me­
diated chloride/bicarbonate ex­
change to recovery of intracellular 
pH in IMR-32 neuroblastoma cells 
after acidosis. A Cells do not recov­
er from an acid load using the 
NH4CI prepulse method [36, 37] in 
the absence of external bicarbon­
ate. B Cells do recover when bicar­
bonate is present. Recovery is com­
pletely inhibited by DIDS, an in­
hibitor of chloride/bicarbonate ex­
change, and a high-affinity ligand 
of AE proteins. This inhibition is, 
at least partly, reversible. C Recov­
ery from an acid load is partially 
independent of the presence of ex­
tracellular sodium, indicating the 
activity of a sodium-independent 
chloride/bicarbonate exchange sys­
tem.
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cellular homeostasis in general [56]. In neu­
rons, regulation of pHi is involved in regula­
tion of voltage-activated calcium signals, and 
neurotransmitter release and uptake [57]. 
These results warrant the conclusion that a 
major consequence of aging- and degenera- 
tion-associated changes in AE proteins in neu­
ronal cells will be a disturbance of the regula­
tion of intracellular pH, with deleterious ef­
fects on neuronal homeostasis and function.
Conclusions
Neuronal aging and degeneration are ac­
companied by changes in AE structure. These 
changes are most conspicuous in the mem­
brane domain, and resemble the alterations 
that occur in aging erythrocytes. In the latter, 
changes in AE1 structure lead to a decrease in 
anion transport capacity, to decreased bind­
ing of the cytoskeleton protein ankyrin, and to 
generation of a neoaritigen. This senescent 
cell-specific antigen is recognized by the im­
mune system, which results in phagocytosis of 
old and damaged cells. Against this back­
ground, establishment of the identity of the 
AE protein(s) involved in neuronal aging and 
degeneration, together with a molecular de­
scription of the accompanying changes in AE 
structure, will illuminate the processes that 
are involved in aging-related loss of mem­
brane integrity. In our view of the central 
position of AE proteins in cellular homeosta­
sis in general, the observed structural changes 
in human neurons may have severe functional 
consequences, similar to those observed in 
aging erythrocytes. A more extensive discus­
sion of the putative mechanism(s) of cell 
death in Alzheimer’s disease, i.e. apoptosis 
and/or necrosis, is beyond the scope of this 
article [58]. However, the major processes in 
both necrosis and apoptosis may well be asso­
ciated with a compromised AE integrity. For
example, AE-mediated anion transport is a 
major factor in regulation of intraneuronal 
pH, and disturbance o f pH  regulation has 
been suggested to be causally associated with 
various stages in the apoptosis process, e.g. 
through activation of a specific endonuclease 
[59, 60], Also, perturbation of the membrane- 
cytoskeleton interaction has been postulated 
to play a m ajor role in the initial stages of neu­
ronal degeneration in AD [61]. The first 
events in this perturbation may very well be 
sought in the interaction of the cytoplasmic 
domain of an AE protein and one or more 
cytoskeletal proteins. The more so, as this 
interaction is regulated by intracellular cal­
cium concentration and state of phosphoryla­
tion [62, 63], both of which are considered to 
be im portant players on the Alzheimer stage 
[64, 65], Another important role, in physio­
logical apoptosis and in the Alzheimer pathol­
ogy, is played by microglia, the macrophages 
of the brain [66]. Normally, plasma mem­
brane integrity is maintained until late in the 
course of the apoptotic process, until mem­
brane-bound cellular remains are removed by 
macrophages, thereby minimizing inflamma­
tion. When the apoptosis load is high, as may 
be the case in AD [58], the microglia clearance 
system may fail, resulting in necrosis, induc­
tion of inflammatory responses, and further 
tissue damage. The putative role of AE-relat- 
ed antigens in the impaired or untimely recog­
nition of dying and dead cells (or fragments) 
by microglia is an as yet unexplored, but fasci­
nating avenue.
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